Klaria Pharma Plans Potential US Launch of Migraine Treatment With Partner

Bitget2026/10/30 07:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Klaria Pharma has finalized a strategy for a potential US launch of Sumatriptan Alginatfilm with a partner.
The BDO-led process targets licensing deals outside Europe or transactions involving most or all assets; no timetable has been set.
Partner CNX Therapeutics plans an imminent European launch, targeting 10-30% of the region’s approximately SEK 1 billion annual sumatriptan market.
The European agreement provides milestone payments and double-digit sales royalties, with significant revenue expected over the next 12 months.
A small tolerability study remains before a US registration application, potentially using US participants or European patients following launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Klaria Pharma Plans Potential US Launch of Migraine Treatment With Partner

You may also like

Crypto prices